Proposed nuclear safety rules threaten stall novartis pluvicto expansion

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 06 Oct, 13:26 UTC

Novartis’ flagship radioligand therapy Pluvicto entered a rapid growth phase recently, driven by FDA approvals in earlier-stage prostate cancer and broader uptake in community settings. But a regulatory overhaul proposed by federal nuclear authorities now threatens to derail that momentum…

science

Sources

• T2Proposed nuclear safety rules threaten stall novartis pluvicto expansionFierce Biotech / Fierce Healthcare / MedCity / GEN06 Oct, 13:26